PropertyValue
?:abstract
  • In December 2019, a cluster of cases with 2019 Novel Coronavirus pneumonia from Wuhan, China, aroused worldwide concern due to an escalating outbreak in all the countries in the world. Coronavirus belongs to a family of single-stranded RNA viruses, which includes severe acute respiratory syndrome (SARS-CoV) and Middle East respiratory syndrome (MERS-CoV), that have caused human epidemics with high fatality. The spectrum of the novel coronavirus disease (SARS-Co-2 or COVID-19) ranges from asymptomatic infections to fatal pneumonia, and differs from other viral pulmonary infections. MERS-CoV is known to be potentially neuroinvasive. Extensive reports from China documented central and peripheral nervous system involvement in patients with COVID-19, and identified in angiotensin converting enzyme2 (ACE2), which is present in multiple human organs, the functional receptor for this virus. Guillain–Barré syndrome (GBS) has recently been associated to COVID-19 rising concern among physicians. This review summarizes the current state of knowledge on GBS during or after COVID-19 infection, attempting to clarify the pathophysiology of the associated respiratory dysfunction and failure.
?:creator
?:doi
  • 10.1007/s13760-020-01421-3
?:doi
?:journal
  • Acta_Neurol_Belg
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/7d5dcd7bd39bfbb147883563097fc3795f33d20c.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7373212.xml.json
?:pmcid
?:pmid
?:pmid
  • 32696312.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC; WHO
?:title
  • Facing acute neuromuscular diseases during COVID-19 pandemic: focus on Guillain–Barré syndrome
?:type
?:year
  • 2020-07-21

Metadata

Anon_0  
expand all